Rockwell Medical Inc (RMTI) - Net Assets
Based on the latest financial reports, Rockwell Medical Inc (RMTI) has net assets worth $35.86 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.42 Million) and total liabilities ($21.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check RMTI goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $35.86 Million |
| % of Total Assets | 62.44% |
| Annual Growth Rate | 11.63% |
| 5-Year Change | 1358.82% |
| 10-Year Change | -30.17% |
| Growth Volatility | 2156.93 |
Rockwell Medical Inc - Net Assets Trend (1997–2025)
This chart illustrates how Rockwell Medical Inc's net assets have evolved over time, based on quarterly financial data. See Rockwell Medical Inc (RMTI) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Rockwell Medical Inc (1997–2025)
The table below shows the annual net assets of Rockwell Medical Inc from 1997 to 2025. For live valuation and market cap data, see RMTI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $36.98 Million | +13.49% |
| 2024-12-31 | $32.59 Million | +53.05% |
| 2023-12-31 | $21.29 Million | +50.94% |
| 2022-12-31 | $14.11 Million | +456.45% |
| 2021-12-31 | $2.54 Million | -92.58% |
| 2020-12-31 | $34.17 Million | +68.16% |
| 2019-12-31 | $20.32 Million | -25.50% |
| 2018-12-31 | $27.28 Million | -17.12% |
| 2017-12-31 | $32.91 Million | -37.85% |
| 2016-12-31 | $52.96 Million | -15.02% |
| 2015-12-31 | $62.32 Million | -9.29% |
| 2014-12-31 | $68.70 Million | +11436.24% |
| 2013-12-31 | $595.54K | +105.98% |
| 2012-12-31 | $-9.96 Million | -154.60% |
| 2011-12-31 | $18.24 Million | -40.25% |
| 2010-12-31 | $30.54 Million | +4.14% |
| 2009-12-31 | $29.32 Million | +148.06% |
| 2008-12-31 | $11.82 Million | -34.19% |
| 2007-12-31 | $17.96 Million | +114.48% |
| 2006-12-31 | $8.37 Million | +117.80% |
| 2005-12-31 | $3.84 Million | +12.34% |
| 2004-12-31 | $3.42 Million | +7.89% |
| 2003-12-31 | $3.17 Million | +4.16% |
| 2002-12-31 | $3.05 Million | +17.29% |
| 2001-12-31 | $2.60 Million | -9.25% |
| 2000-12-31 | $2.86 Million | -20.52% |
| 1999-12-31 | $3.60 Million | -21.74% |
| 1998-12-31 | $4.60 Million | +170.59% |
| 1997-12-31 | $1.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Rockwell Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40109200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.01% |
| Other Comprehensive Income | $131.00K | 0.35% |
| Other Components | $439.84 Million | 1189.36% |
| Total Equity | $36.98 Million | 100.00% |
Rockwell Medical Inc Competitors by Market Cap
The table below lists competitors of Rockwell Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Superlon Holdings Bhd
KLSE:7235
|
$25.68 Million |
|
TPC Consolidated Ltd
AU:TPC
|
$25.68 Million |
|
NTG Clarity Networks Inc.
V:NCI
|
$25.69 Million |
|
Eminent Gold Corp
V:EMNT
|
$25.70 Million |
|
Tongyang Pile Inc
KQ:228340
|
$25.67 Million |
|
Dexter Co Ltd
KQ:206560
|
$25.66 Million |
|
Grande Group Limited Class A Ordinary Shares
NASDAQ:GRAN
|
$25.65 Million |
|
Mohenz.Co.Ltd
KQ:006920
|
$25.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Rockwell Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,586,000 to 36,981,000, a change of 4,395,000 (13.5%).
- Net loss of 5,314,000 reduced equity.
- New share issuances of 7,816,000 increased equity.
- Other comprehensive income increased equity by 77,000.
- Other factors increased equity by 1,816,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.31 Million | -14.37% |
| Share Issuances | $7.82 Million | +21.14% |
| Other Comprehensive Income | $77.00K | +0.21% |
| Other Changes | $1.82 Million | +4.91% |
| Total Change | $- | 13.49% |
Book Value vs Market Value Analysis
This analysis compares Rockwell Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.17x to 0.63x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | $3.79 | $0.65 | x |
| 1998-12-31 | $10.44 | $0.65 | x |
| 1999-12-31 | $7.92 | $0.65 | x |
| 2000-12-31 | $6.48 | $0.65 | x |
| 2001-12-31 | $4.96 | $0.65 | x |
| 2002-12-31 | $4.34 | $0.65 | x |
| 2003-12-31 | $3.67 | $0.65 | x |
| 2004-12-31 | $3.56 | $0.65 | x |
| 2005-12-31 | $4.82 | $0.65 | x |
| 2006-12-31 | $8.26 | $0.65 | x |
| 2007-12-31 | $17.00 | $0.65 | x |
| 2008-12-31 | $9.40 | $0.65 | x |
| 2009-12-31 | $21.69 | $0.65 | x |
| 2010-12-31 | $20.03 | $0.65 | x |
| 2011-12-31 | $11.32 | $0.65 | x |
| 2012-12-31 | $-5.37 | $0.65 | x |
| 2013-12-31 | $0.20 | $0.65 | x |
| 2014-12-31 | $18.25 | $0.65 | x |
| 2015-12-31 | $13.79 | $0.65 | x |
| 2016-12-31 | $11.47 | $0.65 | x |
| 2017-12-31 | $7.12 | $0.65 | x |
| 2018-12-31 | $5.68 | $0.65 | x |
| 2019-12-31 | $3.67 | $0.65 | x |
| 2020-12-31 | $4.97 | $0.65 | x |
| 2021-12-31 | $0.30 | $0.65 | x |
| 2022-12-31 | $1.43 | $0.65 | x |
| 2023-12-31 | $0.91 | $0.65 | x |
| 2024-12-31 | $1.05 | $0.65 | x |
| 2025-12-31 | $1.03 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Rockwell Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.67%
- • Asset Turnover: 1.21x
- • Equity Multiplier: 1.55x
- Recent ROE (-14.37%) is above the historical average (-372.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -111.76% | -57.58% | 0.92x | 2.12x | $-2.07 Million |
| 1998 | -41.30% | -35.85% | 1.00x | 1.15x | $-2.36 Million |
| 1999 | -30.56% | -16.42% | 1.49x | 1.25x | $-1.46 Million |
| 2000 | -35.54% | -13.64% | 1.84x | 1.42x | $-1.30 Million |
| 2001 | -60.81% | -17.52% | 1.49x | 2.33x | $-1.84 Million |
| 2002 | -32.20% | -8.53% | 1.78x | 2.12x | $-1.29 Million |
| 2003 | 0.15% | 0.03% | 2.12x | 2.22x | $-312.36K |
| 2004 | 6.18% | 1.18% | 2.33x | 2.25x | $-130.71K |
| 2005 | 2.00% | 0.28% | 2.99x | 2.41x | $-307.67K |
| 2006 | -54.63% | -15.97% | 2.18x | 1.57x | $-5.41 Million |
| 2007 | -20.71% | -8.64% | 1.89x | 1.27x | $-5.51 Million |
| 2008 | -66.53% | -15.22% | 2.73x | 1.60x | $-9.05 Million |
| 2009 | -18.76% | -10.05% | 1.57x | 1.19x | $-8.43 Million |
| 2010 | -8.79% | -4.51% | 1.61x | 1.21x | $-5.74 Million |
| 2011 | -117.54% | -43.79% | 1.53x | 1.75x | $-23.27 Million |
| 2012 | 0.00% | -108.38% | 2.93x | 0.00x | $-53.03 Million |
| 2013 | -8191.46% | -93.13% | 1.44x | 61.06x | $-48.84 Million |
| 2014 | -31.04% | -39.36% | 0.55x | 1.43x | $-28.20 Million |
| 2015 | -23.14% | -26.05% | 0.63x | 1.41x | $-20.65 Million |
| 2016 | -37.39% | -37.16% | 0.64x | 1.57x | $-25.10 Million |
| 2017 | -78.76% | -45.24% | 0.97x | 1.79x | $-29.21 Million |
| 2018 | -117.78% | -50.68% | 1.21x | 1.93x | $-34.85 Million |
| 2019 | -167.95% | -55.67% | 1.38x | 2.18x | $-36.16 Million |
| 2020 | -90.40% | -49.66% | 0.80x | 2.28x | $-34.31 Million |
| 2021 | -1288.92% | -52.76% | 1.27x | 19.16x | $-32.93 Million |
| 2022 | -132.42% | -25.65% | 1.56x | 3.31x | $-20.09 Million |
| 2023 | -39.64% | -10.09% | 1.60x | 2.45x | $-10.57 Million |
| 2024 | -1.47% | -0.47% | 1.71x | 1.82x | $-3.74 Million |
| 2025 | -14.37% | -7.67% | 1.21x | 1.55x | $-9.01 Million |
Industry Comparison
This section compares Rockwell Medical Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Rockwell Medical Inc (RMTI) | $35.86 Million | -111.76% | 0.60x | $25.68 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About Rockwell Medical Inc
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate conce… Read more